

Ref: EPL/CS/SE/0072/2026

Date: August 8, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Script Symbol: EMCURE	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001 Scrip Code/Symbol: 544210/ EMCURE
--	---

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – Update on USFDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, India.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated May 16, 2026, on the inspection conducted by the United States Food & Drug Administration (“USFDA”) at the Company’s formulations facility located at G.I.D.C., Taluka - Sanand, Ahmedabad – 382110, Gujarat, from May 06, 2026 to May 15, 2026, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the USFDA. The USFDA has classified the inspection status of the said facility as **Voluntary Action Indicated (VAI)** and accordingly, the inspection stands closed.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yangalwar
Company Secretary & Compliance Officer
Membership Number: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251